Different features of ca2+ oscillations in differentiated and undifferentiated hepatocyte doublets

Tsuneo Kitamura, Sumio Watanabe, Ken‐Ichi Ikejima, Miyoko Hirose, Akihisa Miyazaki, Atsuko Yumoto, Satoko Suzuki, Toshio Yamada, Noriyuki Kitami, Nobuhiro Sato – 1 May 1995 – Cytosolic free Ca2+ ([Ca2+]i) oscillations are postulated to play a critical role in cellular proliferation. By using doublets of normal rats (NR) and those 18 hours after two‐thirds hepatectomy (PHR), we investigated cytosolic free Ca2+ ([Ca2+]i) responses in liver regeneration. Normal rat hepatocyte doublets that retain their bile canaliculi are polarized and well differentiated.

Which is the best surgery for budd‐chiari syndrome: Venous decompression or liver transplantation? a single‐center experience with 50 patients

Burckhardt Ringe, Hauke Lang, Karl‐Jürgen Oldhafer, Michael Gebel, Peer Flemming, Axel Georgii, Hans‐Georg Borst, Rudolf Pichlmayr – 1 May 1995 – The optimal treatment of Budd‐Chiari syndrome (BCS) remains an open question. It is still a matter of controversial discussion whether venous decompression or liver transplantation is superior. To elucidate the role and prognosis of both surgical options in our own experience, a consecutive series of 50 patients treated between 1981 and 1993 was retrospectively analyzed.

Sclerotherapy plus octreotide versus sclerotherapy alone in the prevention of early rebleeding from esophageal varices: A randomized, double‐blind, placebo‐controlled, multicenter trial

Massimo Pkimignani, Bruno Andreoni, Luca Carpinelli, Alfonso Capria, Gabriele Rocchi, Ivano Lorenzini, Carlo Staudacher, Luigi Beretta, Roberta Motta, Roberto DeFranchis – 1 May 1995 – Because of its ability to decrease portal pressure, azygos blood flow, and postprandial splanchnic hyperemia, octreotide administration could be effective in reducing early rebleeding in patients undergoing endoscopic variceal sclerotherapy (EVS). We report the results of a trial comparing EVS + octreotide versus EVS alone.

Kupffer cell iron overload induces intercellular adhesion molecule‐1 expression on hepatocytes in genetic hemochromatosis

Per Stå, Ulrika Broomé, Annika Scheynius, Ragnar Befrits, Rolf Hultcrantz – 1 May 1995 – The mechanisms underlying iron‐induced liver fibrogenesis in patients with genetic hemochromatosis are poorly understood. We studied signs of Kupffer cell activation and inflammatory responses in liver biopsy specimens obtained from 15 patients with untreated and six patients with treated hemochromatosis. Immunohisto‐chemistry was performed on 11 of the untreated and all treated patients. Three of the untreated patients (20%) had cirrhosis and eight (53%) had fibrosis.

Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma

Taketoshi Suehiro, Mitsuo Shimada, Takashi Matsumata, Akinobu Taketomi, Kazuharu Yamamoto, Keizo Sugimachi – 1 May 1995 – Thrombomodulin (TM) converts thrombin from procoagulant into anticoagulant protein to activate protein C. Thrombin also plays an important role in the metastatic process of cancer cells. We performed an immunohistochemical and clinicopathological study of TM in 141 cases with resected hepatocellular carcinoma (HCC) measuring less than 6 cm in diameter. Twenty‐five specimens (17.73%) stained positive for TM. TM was found in the cytoplasm and surface of cancer cells.

Ursodeoxycholic acid therapy in primary biliary cirrhosis

David E. J. Jones, Oliver F. W. James, Margaret F. Bassendine – 1 May 1995 – Background/Aims: A double‐blind, placebo‐controlled trial of ursodeoxycholic acid (UDCA) was conducted in 180 patients with primary biliary cirrhosis (PBC) to define the efficacy and safety of UDCA. Efficacy was assessed by time to treatment failure defined as death; liver transplantation; histological progression; development of varices, ascites, or encephalopathy; doubling of total serum bilirubin levels; progression of fatigue or pruritus; drug toxicity; or voluntary withdrawal.

Subscribe to